These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18762765)

  • 1. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.
    Magro L; Catteau B; Coiteux V; Bruno B; Jouet JP; Yakoub-Agha I
    Bone Marrow Transplant; 2008 Dec; 42(11):757-60. PubMed ID: 18762765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of sclerodermatous graft-versus-host disease responsive to imatinib therapy.
    Lazar J; Poonawalla T; Teng JM
    Pediatr Dermatol; 2011; 28(2):172-5. PubMed ID: 21504445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful long-term use of imatinib mesylate in pediatric patients with sclerodermatous chronic GVHD.
    Kim H; Kim NH; Kang HJ; Lee JW; Kim MS; Park KD; Shin HY; Ahn HS
    Pediatr Transplant; 2012 Dec; 16(8):910-2. PubMed ID: 23050745
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease.
    Zerr P; Distler A; Palumbo-Zerr K; Tomcik M; Vollath S; Dees C; Egberts F; Tinazzi I; Del Galdo F; Distler O; Schett G; Spriewald BM; Distler JH
    Am J Pathol; 2012 Nov; 181(5):1672-80. PubMed ID: 22940072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is imatinib mesylate a promising drug in systemic sclerosis?
    van Daele PL; Dik WA; Thio HB; van Hal PT; van Laar JA; Hooijkaas H; van Hagen PM
    Arthritis Rheum; 2008 Aug; 58(8):2549-52. PubMed ID: 18668570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating endothelial progenitor cells decreased in patients with sclerodermatous chronic graft-versus-host disease.
    Shimura K; Ashihara E; Shimazaki C; Matsunaga S; Taniguchi K; Uchiyama H; Matsumoto Y; Kimura S; Matsubara H; Taniwaki M; Maekawa T
    Biol Blood Marrow Transplant; 2008 Apr; 14(4):426-37. PubMed ID: 18342785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study.
    Soria A; Cario-André M; Lepreux S; Rezvani HR; Pasquet JM; Pain C; Schaeverbeke T; Mahon FX; Taïeb A
    Dermatology; 2008; 216(2):109-17. PubMed ID: 18216472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term extracorporeal photochemotherapy in a pediatric patient with refractory sclerodermatous chronic graft-versus-host disease.
    Bisaccia E; Palangio M; Gonzalez J
    Transfus Apher Sci; 2011 Oct; 45(2):187-90. PubMed ID: 21890415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate inhibits proliferation and exerts an antifibrotic effect in human breast stroma fibroblasts.
    Gioni V; Karampinas T; Voutsinas G; Roussidis AE; Papadopoulos S; Karamanos NK; Kletsas D
    Mol Cancer Res; 2008 May; 6(5):706-14. PubMed ID: 18505916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
    Distler JH; Distler O
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.
    Molés-Poveda P; Montesinos P; Sanz-Caballer J; de Unamuno B; Piñana JL; Sahuquillo A; Botella-Estrada R
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):241-247. PubMed ID: 29254596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate treatment of nephrogenic systemic fibrosis.
    Kay J; High WA
    Arthritis Rheum; 2008 Aug; 58(8):2543-8. PubMed ID: 18668587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.
    de Masson A; Bouaziz JD; Peffault de Latour R; Wittnebel S; Ribaud P; Rubio MT; Micol JB; Suarez F; Nguyen S; Dalle JH; Yakouben K; Robin M; Xhaard A; Adès L; Bourhis JH; Rybojad M; Bagot M; Socié G
    Blood; 2012 Dec; 120(25):5089-90. PubMed ID: 23243159
    [No Abstract]   [Full Text] [Related]  

  • 15. Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases.
    Mueller L; Goumas FA; Himpel S; Brilloff S; Rogiers X; Broering DC
    Cancer Lett; 2007 Jun; 250(2):329-38. PubMed ID: 17141949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sarpogrelate hydrochloride in a patient with chronic graft-versus-host disease: a case report.
    Hayashi T; Morishita E; Ontachi Y; Yamazaki M; Asakura H; Yoshida T; Nakao S
    Am J Hematol; 2006 Feb; 81(2):121-3. PubMed ID: 16432874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease.
    Belle L; Fransolet G; Somja J; Binsfeld M; Delvenne P; Drion P; Hannon M; Beguin Y; Ehx G; Baron F
    PLoS One; 2016; 11(12):e0167997. PubMed ID: 27942010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
    Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
    Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD.
    Andree H; Hilgendorf I; Leithaeuser M; Junghanss C; Holzhueter S; Loddenkemper C; Steiner B; Freund M; Wolff D
    Bone Marrow Transplant; 2008 Oct; 42(8):541-6. PubMed ID: 18641680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice.
    Pai CS; Khuat LT; Chen M; Murphy WJ; Abedi M
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):30-37. PubMed ID: 27815049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.